Results 1 to 3 of 3

Thread: Israeli Reports: Dramatic Change in Patient with ALS and MG following Compassionate U

  1. #1

    Thumbs up Israeli Reports: Dramatic Change in Patient with ALS and MG following Compassionate U

    Israeli Channel 2 TV interviewed today a patient suffering from Myasthenia Gravis (MG) and recently diagnosed with ALS. The patient reported that he has experienced visible improvement in his speech, walking, balance, posture, muscle strength, appetite, digestion, and weight gain following compassionate treatment with BrainStorm’s NurOwn cell therapy.
    “Due to the rare disease combination of MG and ALS, this patient was approved for compassionate treatment with BrainStorm’s NurOwn cell therapy,” says Professor Dimitrios Karussis of the Neurology Department at The Hadassah Medical Center in Jerusalem, and Principal Investigator of BrainStorm’s current Phase I/II clinical trial. “Within a few weeks following injection with NurOwn cells, the patient showed dramatic improvement in a variety of functions including breathing, speech, walking, muscular strength, and overall well-being. While we cannot draw scientific conclusions based on the outcome of an individual patient, these results are extremely encouraging.”
    “We are moved by the remarkable results observed following treatment with NurOwn,” said Professor Avi Israeli, BrainStorm’s Chairman of the Board. “We are hopeful that we will continue to see this kind of improvement in all the patients participating in our current and future clinical trials.”
    In January 2012 the Company reported initial safety data from the first four patients in BrainStorm’s ALS Phase I/II human clinical trial, indicating that treatment with NurOwn did not present any significant side effects and demonstrated some beneficial clinical effects. After reviewing this safety data, the Hadassah Medical Center ethical committee granted approval for the trial to continue. Interim results for the first 12 patients are expected in July 2012.
    BrainStorm expects to expand its ALS clinical development into the United States. Orphan-drug designation for NurOwn has been granted by the US Food and Drug Administration. In addition, the Company has entered into a Memorandum of Understanding with the University of Massachusetts Medical School and Massachusetts General Hospital to begin ALS human clinical trials at these institutions.
    "I'm manic as hell-
    But I'm goin' strong-
    Left my meds on the sink again-
    My head will be racing by lunchtime"

    <----Scott Weiland---->

  2. #2
    Thanks for this information. It is fortunate that there has been an increase of money going toward ALS research.


  3. #3

    Thumbs up Compassionate Patient Interview on Israeli Channel 2 TV with English Captions

    More on the NurOwn treatment of neurodegenerative diseases, video included.

    NEW YORK & PETACH TIKVAH, Israel–(BUSINESS WIRE)– Brainstorm Cell Therapeutics Inc (BCLI:$0.312,0$-0.005,0-1.58%) , as per the request of many of our English speaking shareholders, following is a link to view the interview on Israeli Channel 2 news with English subtitles –
    About BrainStorm Cell Therapeutics, Inc. (BCLI:$0.312,0$-0.005,0-1.58%)
    BrainStorm Cell Therapeutics Inc. (BCLI:$0.312,0$-0.005,0-1.58%) is a biotechnology company engaged in the development of adult stem cell therapeutic products derived from autologous bone marrow cells and intended for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn™ technology through an exclusive, worldwide licensing agreement with Ramot at Tel Aviv University Ltd., the technology transfer company of Tel-Aviv University. For more information, visit the company’s new website at
    "I'm manic as hell-
    But I'm goin' strong-
    Left my meds on the sink again-
    My head will be racing by lunchtime"

    <----Scott Weiland---->

Similar Threads

  1. Spinal Cord Research: Brief History ... Dramatic Life Change
    By Max in forum Recreation, Sports, Travel, & Hobbies
    Replies: 0
    Last Post: 07-30-2007, 05:40 PM
  2. Replies: 3
    Last Post: 10-11-2006, 06:23 AM
  3. Replies: 13
    Last Post: 04-01-2005, 06:26 PM

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts